This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moving Average Crossover Alert: Cellectis
by Zacks Equity Research
Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CLLS) Outperforming Other Medical Stocks This Year?
Cellectis' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cellectis.
How Cellectis (CLLS) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 12th.
What Makes Cellectis S.A. (CLLS) a New Strong Buy Stock
by Zacks Equity Research
Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectis Enters Oversold Territory
by Zacks Equity Research
Cellectis has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
by Ekta Bagri
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
Company News For Dec 14, 2017
by Zacks Equity Research
Companies in the news are: CIVI,CLLS,PAY,FNSR,AAPL
Company News For Sep 6, 2017
by Zacks Equity Research
Companies in the news are: INSM,CLLS,FUL,GOOGL
Cellectis (CLLS) Catches Eye: Stock Jumps 17%
by Zacks Equity Research
Cellectis (CLLS) shares rose 17% in the last trading session, amid huge volumes.
New Strong Buy Stocks for July 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
New Strong Buy Stocks for July 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Strength Seen in Cellectis S.A. (CLLS): Stock Soars 8.95%
by Zacks Equity Research
Cellectis S.A. (CLLS) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
3 Biotech Stocks That Are Broker Favorites
by Arpita Dutt
These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).
Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose above 6% on the day.
VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period
Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) reported a fourth-quarter 2016 loss of $2.04 per share (including the impact of stock-based compensation expenses), wider than both the Zacks Consensus Estimate of a loss of $2.02.
Juno (JUNO) Loss Wider; End of Cancer Drug Study Hits Stock
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) reported wider-than-expected loss in the fourth quarter of 2016. Shares of the company declined as it announced that it has decided not to move forward with the ROCKET trial or cancer candidate JCAR015.
Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported fourth-quarter 2016 earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.65.
Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported fourth-quarter 2016 loss of $1.86 per share, wider than both the Zacks Consensus Estimate of a loss of $1.64 and the year-ago loss of $1.02.
Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Emergent BioSolutions, Inc. (EBS) reported earnings of 74 cents per share in the fourth quarter of 2016, which surpassed the Zacks Consensus Estimate of 60 cents. However, the reported figure decreased from 77 cents earned in the year-ago period.
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.
Bear of the Day: Seattle Genetics (SGEN)
by Brian Hamilton
Seattle Genetics recently reported both a top and bottom line miss, and reduced 2017 sales expectations.